SCHEMBL26388338

SCHEMBL26388338

COc1ccc(CC23CCC(NC(=O)OC(C)(C)C)(CC2)CC3)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PPARG P37231 1/20 0.42
PPARA Q07869 1/20 0.42
CACNA1B Q00975 2/20 0.40
PPIA P62937 2/20 0.39
HTT P42858 1/20 0.39
ALDH1A1 P00352 4/20 0.39
LMNA P02545 3/20 0.39
NPSR1 Q6W5P4 1/20 0.39
F2RL1 P55085 1/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
MAPT P10636 1/20 0.38
MEN1 O00255 1/20 0.38
NPC1 O15118 1/20 0.38
EPHX2 P34913 1/20 0.38
RAB9A P51151 1/20 0.38
KMT2A Q03164 1/20 0.38
NR1H4 Q96RI1 1/20 0.38
L3MBTL1 Q9Y468 1/20 0.38
SAE1 Q9UBE0 1/20 0.37
UBA2 Q9UBT2 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26387945 0.88 PPARG (0.42) PPARGPPARACACNA1BPPIAHTT
SCHEMBL24622411 0.84 EPHX2 (0.37) PPARGPPARAPPIAALDH1A1SMN1; SMN2
SCHEMBL26388320 0.79 PPIA (0.43) PPARGPPARACACNA1BPPIAHTT
SCHEMBL26388248 0.76 PPARG (0.41) PPARGPPARACACNA1BHTTALDH1A1
SCHEMBL8355292 0.75 CA12 (0.41) PPARGPPARACACNA1BHTTALDH1A1
SCHEMBL15979034 0.75 MEN1 (0.37) MEN1EPHX2KMT2A
SCHEMBL28392276 0.75 LMNA (0.43) PPARGPPARACACNA1BALDH1A1LMNA
SCHEMBL24622302 0.74 LOXL2 (0.47) ALDH1A1SMN1; SMN2MAPTNPC1EPHX2
SCHEMBL15979024 0.74 MEN1 (0.39) MEN1KMT2A
SCHEMBL15979029 0.74 KMT2A (0.39) ALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF IMMUNEXT INC (US) 2023-10-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230310634-A1 ANTI-HUMAN VISTA ANTIBODIES AND USE THEREOF CD47, CLTA, FCGR2A PPARG 1793/4885PPARA 914/4885CACNA1B 3900/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.